Head-to-Head Trial Pits Two Modified-Release Hydrocortisones Against Each Other
A Phase II crossover trial directly compares Chronocort and Plenadren to find the optimal hydrocortisone replacement for adrenal insufficiency.
Summary
People with primary adrenal insufficiency must take hydrocortisone for life, but standard tablets create unnatural cortisol spikes and troughs. Two modified-release formulations — Chronocort, taken twice daily, and Plenadren, taken once daily — aim to mimic the body's natural cortisol rhythm more closely. This completed Phase II crossover trial enrolled adults at six sites across two countries and directly compared the two drugs head-to-head over roughly two months each. Participants experienced both treatments in randomized order, allowing a within-person comparison of efficacy, safety, and tolerability. Results from this trial could guide clinicians toward the formulation that best restores physiological cortisol patterns, potentially improving patients' quality of life, metabolic health, and long-term outcomes.
Detailed Summary
For people living with primary adrenal insufficiency, replacing cortisol is a lifelong necessity. The conventional approach — immediate-release hydrocortisone taken multiple times daily — produces artificial peaks and valleys in cortisol that fail to replicate the body's natural circadian rhythm. Poor cortisol patterning is linked to fatigue, metabolic dysfunction, cardiovascular risk, and reduced quality of life, making better replacement strategies a genuine clinical priority.
This Phase II study set out to directly compare two modified-release hydrocortisone formulations: Chronocort (twice daily) and Plenadren (once daily). Both are engineered to release cortisol more gradually and in a pattern that better approximates physiological secretion, but they differ in dosing schedule and release kinetics. The randomized, double-blind, double-dummy crossover design meant each participant received both treatments sequentially, serving as their own control — a rigorous approach well-suited to detecting differences between active comparators.
The trial was conducted at approximately six investigational sites across two countries and enrolled adults aged 18 and older with confirmed primary adrenal insufficiency. Each treatment period lasted up to two months. The primary endpoints focused on efficacy, safety, and tolerability, though specific outcome measures are not detailed in the publicly available abstract.
For clinicians managing adrenal insufficiency, the findings carry practical weight. If one formulation demonstrably better restores circadian cortisol profiles, that could translate into meaningful improvements in patient energy levels, metabolic markers, immune function, and long-term cardiovascular health. The once-daily convenience of Plenadren versus the potentially superior circadian mimicry of twice-daily Chronocort represents a real clinical trade-off worth quantifying.
The trial has been completed under the sponsorship of Neurocrine UK Limited. Because only the abstract and registry entry are publicly available, detailed results, adverse event rates, and quantitative outcome data cannot yet be assessed. Publication of full results is awaited.
Key Findings
- Phase II crossover design allowed direct within-person comparison of Chronocort vs. Plenadren over ~2 months each.
- Both drugs are modified-release hydrocortisone formulations designed to better mimic natural cortisol rhythms than standard tablets.
- Chronocort is dosed twice daily; Plenadren once daily — a clinically meaningful difference in patient adherence burden.
- Trial is completed, but full efficacy and safety results are not yet available in the public domain.
- Optimizing cortisol replacement may improve fatigue, metabolic health, and cardiovascular outcomes in adrenal insufficiency patients.
Methodology
This was a double-blind, double-dummy, two-way crossover randomized Phase II trial conducted at approximately six sites in two countries. Adults with primary adrenal insufficiency were randomized to receive each treatment sequentially, with each period lasting up to two months. The crossover design controls for inter-individual variability, strengthening the comparative analysis.
Study Limitations
The summary is based on the abstract and clinical trial registry entry only, as the full study results are not publicly available; efficacy endpoints, quantitative outcomes, and adverse event data cannot be evaluated. The two-month treatment periods may be insufficient to capture long-term tolerability differences. As a Phase II study, the sample size is likely modest and may not be powered to detect rare adverse events.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.